Literature DB >> 11430529

Cardiac nuclear medicine in monitoring patients with coronary heart disease.

J A Parker1.   

Abstract

Patient monitoring is a major indication for cardiac nuclear medicine procedures. Stress myocardial perfusion scintigraphy was initially used for diagnosis, but monitoring patients with coronary artery disease has become more common. Stress myocardial perfusion scintigraphy has been shown to provide a considerable amount of incremental prognostic information, which may be useful in selecting patients for therapy. In patients being considered for revascularization, fluorodeoxyglucose can be used to identify regions of dysfunctional but viable myocardium, even within regions that show fixed defects on stress perfusion imaging. It can be used to select a group of patients who will improve function with revascularization and who may have an improved outcome. Thus, cardiac nuclear medicine plays a pivotal role in monitoring patients with coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430529     DOI: 10.1053/snuc.2001.23529

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  9 in total

1.  64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics.

Authors:  Chang-Tong Yang; Young-Seung Kim; Jianjun Wang; Lijun Wang; Jiyun Shi; Zi-Bo Li; Xiaoyuan Chen; Ming Fan; Jian-Jian Li; Shuang Liu
Journal:  Bioconjug Chem       Date:  2008-09-03       Impact factor: 4.774

2.  Minimizing liver uptake of cationic Tc radiotracers with ether and crown ether functional groups.

Authors:  Young-Seung Kim; Fan Wang; Shuang Liu
Journal:  World J Hepatol       Date:  2010-01-27

Review 3.  64Cu-labeled phosphonium cations as PET radiotracers for tumor imaging.

Authors:  Yang Zhou; Shuang Liu
Journal:  Bioconjug Chem       Date:  2011-07-01       Impact factor: 4.774

Review 4.  Technetium-99m Radiopharmaceuticals for Ideal Myocardial Perfusion Imaging: Lost and Found Opportunities.

Authors:  Alessandra Boschi; Licia Uccelli; Lorenza Marvelli; Corrado Cittanti; Melchiore Giganti; Petra Martini
Journal:  Molecules       Date:  2022-02-10       Impact factor: 4.411

5.  Tc-99m-N-MPO: novel cationic Tc-99m radiotracer for myocardial perfusion imaging.

Authors:  Young-Seung Kim; Jianjun Wang; Alexis Broisat; David K Glover; Shuang Liu
Journal:  J Nucl Cardiol       Date:  2008-04-21       Impact factor: 5.952

6.  Mechanism for myocardial localization and rapid liver clearance of Tc-99m-N-MPO: a new perfusion radiotracer for heart imaging.

Authors:  Young-Seung Kim; Jiyun Shi; Shizhen Zhai; Guihua Hou; Shuang Liu
Journal:  J Nucl Cardiol       Date:  2009-03-14       Impact factor: 5.952

7.  Effect of co-ligands on chemical and biological properties of (99m)Tc(III) complexes [(99m)Tc(L)(CDO)(CDOH)2BMe] (L=Cl, F, SCN and N3; CDOH2=cyclohexanedione dioxime).

Authors:  Yumin Zheng; Shundong Ji; Elena Tomaselli; Carley Ernest; Tom Freiji; Shuang Liu
Journal:  Nucl Med Biol       Date:  2014-08-01       Impact factor: 2.408

8.  Development of kit formulations for (99m) TcN-MPO: a cationic radiotracer for myocardial perfusion imaging.

Authors:  Yumin Zheng; Shundong Ji; Elena Tomaselli; Shuang Liu
Journal:  J Labelled Comp Radiopharm       Date:  2014-07-28       Impact factor: 1.921

9.  Imaging probes for non-invasive tumoral detection and functional monitoring of cancer multidrug resistance.

Authors:  Filipa Mendes; Lurdes Gano; Jorge Grilo; Susana Cunha; Célia Fernandes; António Paulo
Journal:  Cancer Drug Resist       Date:  2020-02-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.